Press releases
- Glaukos Announces the Release of its 2023 Sustainability Report
- Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
- Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
- Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
- Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
- Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
More ▼
Key statistics
As of last trade Glaukos Corp (6GJ:FRA) traded at 92.50, -1.07% below its 52-week high of 93.50, set on Apr 24, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 92.50 |
---|---|
High | 92.50 |
Low | 92.50 |
Bid | 92.00 |
Offer | 93.50 |
Previous close | 92.50 |
Average volume | 29.67 |
---|---|
Shares outstanding | 49.98m |
Free float | 48.22m |
P/E (TTM) | -- |
Market cap | 5.00bn USD |
EPS (TTM) | -2.78 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:16 BST.
More ▼